January 08, 2016
1 min watch
Save

VIDEO: Arsenic plus decitabine effective for MDS, AML

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

ORLANDO — Patricia Kropf, MD, discusses study results she presented at the ASH Annual Meeting and Exposition that showed the combination of arsenic and decitabine induced improved response rates in patients with myelodysplastic syndrome and acute myeloid leukemia.